Barclays PLC Sells 42,724 Shares of AtriCure, Inc. (NASDAQ:ATRC)

Barclays PLC cut its holdings in AtriCure, Inc. (NASDAQ:ATRC - Free Report) by 33.1% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 86,541 shares of the medical device company's stock after selling 42,724 shares during the period. Barclays PLC owned approximately 0.18% of AtriCure worth $2,644,000 at the end of the most recent reporting period.

Other hedge funds have also added to or reduced their stakes in the company. Blue Trust Inc. increased its holdings in shares of AtriCure by 1.8% in the fourth quarter. Blue Trust Inc. now owns 14,751 shares of the medical device company's stock worth $414,000 after buying an additional 265 shares during the period. Invesco Ltd. lifted its position in AtriCure by 0.8% in the fourth quarter. Invesco Ltd. now owns 43,647 shares of the medical device company's stock valued at $1,334,000 after purchasing an additional 334 shares during the last quarter. Perkins Capital Management Inc. boosted its stake in shares of AtriCure by 1.3% during the fourth quarter. Perkins Capital Management Inc. now owns 30,350 shares of the medical device company's stock valued at $927,000 after purchasing an additional 400 shares during the period. Truist Financial Corp grew its holdings in shares of AtriCure by 2.6% in the fourth quarter. Truist Financial Corp now owns 15,717 shares of the medical device company's stock worth $480,000 after purchasing an additional 403 shares during the last quarter. Finally, Franklin Resources Inc. increased its stake in shares of AtriCure by 0.9% in the third quarter. Franklin Resources Inc. now owns 56,843 shares of the medical device company's stock worth $1,569,000 after buying an additional 484 shares during the period. 99.11% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have weighed in on ATRC shares. Canaccord Genuity Group dropped their price target on shares of AtriCure from $66.00 to $52.00 and set a "buy" rating for the company in a research report on Friday, March 28th. BTIG Research restated a "buy" rating on shares of AtriCure in a report on Thursday, March 27th. UBS Group dropped their price objective on AtriCure from $60.00 to $58.00 and set a "buy" rating for the company in a report on Wednesday. Piper Sandler boosted their target price on AtriCure from $40.00 to $50.00 and gave the company an "overweight" rating in a research note on Thursday, February 13th. Finally, Oppenheimer raised their price target on AtriCure from $36.00 to $45.00 and gave the stock an "outperform" rating in a research note on Thursday, February 13th. One investment analyst has rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $50.67.

AtriCure Stock Up 2.5 %

Shares of ATRC stock traded up $0.73 during mid-day trading on Friday, reaching $30.02. 855,143 shares of the company's stock traded hands, compared to its average volume of 655,816. The company's 50-day moving average price is $33.57 and its 200-day moving average price is $34.68. The company has a market cap of $1.49 billion, a P/E ratio of -31.60 and a beta of 1.65. The company has a quick ratio of 2.62, a current ratio of 3.65 and a debt-to-equity ratio of 0.13. AtriCure, Inc. has a 12 month low of $18.94 and a 12 month high of $43.11.

AtriCure (NASDAQ:ATRC - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The medical device company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.11. AtriCure had a negative net margin of 9.61% and a negative return on equity of 6.80%. The business had revenue of $123.62 million for the quarter, compared to analyst estimates of $122.92 million. During the same quarter in the previous year, the firm posted ($0.28) earnings per share. AtriCure's quarterly revenue was up 13.5% on a year-over-year basis. On average, equities analysts expect that AtriCure, Inc. will post -0.6 earnings per share for the current fiscal year.

Insider Transactions at AtriCure

In other AtriCure news, Director Karen Prange sold 6,100 shares of the firm's stock in a transaction dated Wednesday, March 5th. The shares were sold at an average price of $38.12, for a total transaction of $232,532.00. Following the completion of the sale, the director now directly owns 17,828 shares in the company, valued at approximately $679,603.36. This trade represents a 25.49 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 3.50% of the company's stock.

AtriCure Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.